PL3319609T3 - Kompozycje i sposoby stosowania kombinacji leków przeciwbakteryjnych - Google Patents

Kompozycje i sposoby stosowania kombinacji leków przeciwbakteryjnych

Info

Publication number
PL3319609T3
PL3319609T3 PL16822054.9T PL16822054T PL3319609T3 PL 3319609 T3 PL3319609 T3 PL 3319609T3 PL 16822054 T PL16822054 T PL 16822054T PL 3319609 T3 PL3319609 T3 PL 3319609T3
Authority
PL
Poland
Prior art keywords
compositions
methods
drug combinations
antibacterial drug
antibacterial
Prior art date
Application number
PL16822054.9T
Other languages
English (en)
Inventor
Gautam Dantas
Patrick GONZALES
Kevin Forsberg
Mitchell PESESKY
Mayland Chang
Shahriar Mobashery
Original Assignee
Washington University
University Of Notre Dame Du Lac
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University, University Of Notre Dame Du Lac filed Critical Washington University
Publication of PL3319609T3 publication Critical patent/PL3319609T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/424Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL16822054.9T 2015-07-09 2016-07-08 Kompozycje i sposoby stosowania kombinacji leków przeciwbakteryjnych PL3319609T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562190588P 2015-07-09 2015-07-09
PCT/US2016/041565 WO2017008034A1 (en) 2015-07-09 2016-07-08 Compositions and methods of use of antibacterial drug combinations

Publications (1)

Publication Number Publication Date
PL3319609T3 true PL3319609T3 (pl) 2022-12-05

Family

ID=57686086

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16822054.9T PL3319609T3 (pl) 2015-07-09 2016-07-08 Kompozycje i sposoby stosowania kombinacji leków przeciwbakteryjnych

Country Status (10)

Country Link
US (3) US10500191B2 (pl)
EP (2) EP4112057A1 (pl)
JP (3) JP6845511B2 (pl)
CN (2) CN108289896B (pl)
DK (1) DK3319609T3 (pl)
ES (1) ES2929058T3 (pl)
HK (1) HK1258393A1 (pl)
PL (1) PL3319609T3 (pl)
PT (1) PT3319609T (pl)
WO (1) WO2017008034A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6845511B2 (ja) 2015-07-09 2021-03-17 ワシントン・ユニバーシティWashington University 抗細菌性薬剤併用物の組成物及び使用方法
CN107789355B (zh) * 2016-09-07 2022-04-12 湘北威尔曼制药股份有限公司 含有哌拉西林的复方药物组合物及其应用
US10434089B2 (en) 2017-01-25 2019-10-08 The Johns Hopkins University Avibactam and carbapenems antibacterial agents
CN111184866B (zh) * 2018-11-14 2023-12-19 香港中文大学 细菌感染的组合治疗
CN110279692A (zh) * 2019-07-17 2019-09-27 中南大学湘雅二医院 一种抗感染组合物、制剂及其应用
GB202100378D0 (en) * 2021-01-12 2021-02-24 Quadram Inst Bioscience Methods and compositions for antibiotic potentiation
CN113559099A (zh) * 2021-08-27 2021-10-29 丹诺医药(苏州)有限公司 包含舒巴坦和阿维巴坦的药物组合物及其应用
WO2024010495A1 (ru) * 2022-07-05 2024-01-11 Сергей Владимирович СИДОРЕНКО Средство для лечения инфекций, вызванных множественно-устойчивыми бактериями
CN115778949A (zh) * 2022-12-15 2023-03-14 复旦大学附属华山医院 用于抑制产kpc酶肺炎克雷伯菌的组合物、药物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1565456A (zh) * 2003-06-14 2005-01-19 张哲峰 一种头孢吡肟抗菌组合药物
WO2008141764A1 (en) 2007-05-21 2008-11-27 Hans Rudolf Pfaendler Bactericidal anti-mrsa active pharmaceutical composition containing carbapenems
WO2010025328A1 (en) 2008-08-28 2010-03-04 Forest Laboratories Holdings Limited Compositions and methods of treatment comprising ceftaroline
CN102349897B (zh) * 2011-07-22 2012-12-26 深圳市新泰医药有限公司 一种美罗培南钠/他唑巴坦钠药物组合物
AU2011373912B2 (en) 2011-07-26 2016-09-29 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
WO2013085152A1 (en) 2011-12-07 2013-06-13 Union Korea Pharm Co., Ltd. Combined antibiotics comprising cephalosporins and beta-lactamase inhibitors
RU2646798C2 (ru) 2012-09-03 2018-03-07 Вокхардт Лимитед Антибактериальные композиции
GB201306980D0 (en) 2013-04-17 2013-05-29 Blueberry Therapeutics Ltd Methods
JP6917901B2 (ja) 2015-04-30 2021-08-11 ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレート 多環式インドリン化合物及びインドレニン化合物
JP6845511B2 (ja) 2015-07-09 2021-03-17 ワシントン・ユニバーシティWashington University 抗細菌性薬剤併用物の組成物及び使用方法
WO2017203266A1 (en) 2016-05-25 2017-11-30 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections

Also Published As

Publication number Publication date
PT3319609T (pt) 2022-08-23
HK1258393A1 (zh) 2019-11-08
JP2022141948A (ja) 2022-09-29
US20200054605A1 (en) 2020-02-20
JP6845511B2 (ja) 2021-03-17
EP3319609B1 (en) 2022-06-15
US10500191B2 (en) 2019-12-10
EP3319609A1 (en) 2018-05-16
ES2929058T3 (es) 2022-11-24
CN108289896B (zh) 2022-03-01
US20180200226A1 (en) 2018-07-19
JP2018525434A (ja) 2018-09-06
EP3319609A4 (en) 2018-12-12
EP4112057A1 (en) 2023-01-04
JP7121954B2 (ja) 2022-08-19
CN108289896A (zh) 2018-07-17
US11559514B2 (en) 2023-01-24
DK3319609T3 (da) 2022-08-22
US20230293488A1 (en) 2023-09-21
WO2017008034A1 (en) 2017-01-12
CN114796499A (zh) 2022-07-29
JP2021075560A (ja) 2021-05-20

Similar Documents

Publication Publication Date Title
HK1254525A1 (zh) 治療組合物、組合和使用方法
HK1256608A1 (zh) 類黃酮組合物及其使用方法
HK1258393A1 (zh) 抗菌藥物組合的組合物和使用方法
IL259246A (en) Preparations containing pharmaceutical substances and methods of using them
HK1258704A1 (zh) 藥物組合物和塗料
HK1249118A1 (zh) 原毒素-ii變體及使用方法
HK1243354B (zh) 新穎碘伏組合物及其使用方法
IL280690A (en) Pharmaceutical preparations that include DGLA and their use
HK1250476A1 (zh) 原毒素-ii變體及使用方法
FI3380525T3 (fi) Lääkeformulaatioita ja niiden käyttömenetelmiä
IL254783B (en) Combinations for deworming methods for using them
HK1231395A1 (zh) 生物活性血紅素過氧化物酶組合物和使用方法
HK1245113A1 (zh) 藥物組合物及其用途
GB201511799D0 (en) Composition and methods of treatment
HK1243404A1 (zh) 色酰胺組合物和使用方法
PT3503885T (pt) Composição farmacêutica e métodos de utilização
HK1258765A1 (zh) 治療性化合物、組合物和它們的使用方法
HK1248527A1 (zh) 牙科組合物和使用方法
GB2540688B (en) Self-regenerating antimicrobial composition and method of use
IL261794A (en) Preparations and methods for using them
ZA201706950B (en) Antibacterial compositions and methods
IL247645A0 (en) Preparations of seleno-organic compounds and methods of using them
ZA201801120B (en) Oxazolidinone compounds and methods of use thereof as antibacterial agents